Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulations. With the publication of this announcement, this information is now considered to be in the public domain.
8 December 2025
Proteome Sciences plc
("Proteome Sciences" or the "Company")
Substantial contract for Proteome Sciences
Proteome Sciences (AIM:PRM), is pleased to announce that the Company has secured a third contract from a US biopharmaceutical company using the Company's mass spectrometry services to develop a new assay at the company's facilities in Frankfurt, Germany in anticipation of starting a new clinical trial programme next year.
The initial contract will be designed to comply with Good Clinical Laboratory Practice ("GCLP") accreditation and when completed, the new assay will be used to analyse samples from a forthcoming clinical trial due to start at the end of Q1 2026. The next phases of work are anticipated to be similar to the contracts announced in February 2025. A proportion of the work should be completed in the current financial year, with the remainder by the end of Q1 2026.
Commenting on the contract, Richard Dennis, Chief Commercial Officer of Proteome Sciences said:
"We expected to receive additional contracts from the same customer and the targeted assay that we develop is designed to perform under GCLP compliance to monitor drug performance in the new clinical trial planned for early 2026. As in 2024, we continue to see increasing interest for GCLP contracts from other major biopharma clients both in the US and Europe and we hope to secure additional orders in 2026 and 2027."
- Ends -
For further information:
|
||||||||||||||
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences plc is a specialist provider of contract proteomics services to enable drug discovery, development and biomarker identification, and employs proprietary workflows for the optimum analysis of tissues, cells and body fluids. SysQuant® and TMT®MS2 are unbiased methods for identifying and contextualising new targets and defining mechanisms of biological activity, while analysis using Super-Depletion and TMTcalibrator™ provides access to over 8,500 circulating plasma proteins for the discovery of disease-related biomarkers. Targeted assay development using mass spectrometry delivers high sensitivity, interference-free biomarker analyses in situations where standard ELISA assays are not available.